Key result
Biventricular pacing increases walking distance by ~20% at 12 months in heart failure.
Why the study?
The long-term sustainability of benefits from biventricular pacing in patients with NYHA class III heart failure and intraventricular conduction delay was unclear.
Does biventricular pacing improve functional capacity and quality of life in patients with NYHA class III heart failure and intraventricular conduction delay?
RCT (n=131)
randomized
Yes
Does biventricular pacing improve functional capacity and quality of life in patients with NYHA class III heart failure and intraventricular conduction delay?
Answers are grounded in this paper and cite their sources.
Biventricular pacing provides sustained improvements in functional capacity, quality of life, and left ventricular function over 12 months in patients with NYHA class III heart failure and intraventricular conduction delay.
OBJECTIVES: The main objective of this study was to assess if the benefits of biventricular (BiV) pacing observed during the crossover phase were sustained over 12 months. BACKGROUND: MUltisite STimulation In Cardiomyopathies (MUSTIC) is a randomized controlled study intended to evaluate the effects of BiV pacing in patients with New York Heart Association (NYHA) class III heart failure and intraventricular conduction delay. METHODS: Of 131 patients included, 42/67 in sinus rhythm (SR) and 33/64 in atrial fibrillation (AF) were followed up longitudinally at 9 and 12 months by 6-min walked distance, peak oxygen uptake (peak VO(2)), quality of life by the Minnesota score, NYHA class, echocardiography, and left ventricular ejection fraction by radionuclide technique. RESULTS: At 12 months, all SR and 88% of AF patients were programmed to BiV pacing. Compared with baseline, the 6-min walked distance increased by 20% (SR) (p = 0.0001) and 17% (AF) (p = 0.004); the peak VO(2) by 11% (SR) and 9% (AF); quality of life improved by 36% (SR) (p = 0.0001) and 32% (AF) (p = 0.002); NYHA class improved by 25% (SR) (p = 0.0001) and 27% (AF) (p = 0.0001). The ejection fraction improved by 5% (SR) and 4% (AF). Mitral regurgitation decreased by 45% (SR) and 50% (AF). CONCLUSIONS: The clinical benefits of BiV pacing appeared to be significantly maintained over a 12-month follow-up period.
No takes yet. Share an insight, caveat, or question.
Linde et al. (2002) conducted an RCT in congestive heart failure (n=131). Biventricular pacing vs. Baseline was evaluated on 6-min walked distance (p=0.0001). Biventricular pacing maintained clinical benefits at 12 months in heart failure patients, increasing walking distance by 20% in sinus rhythm and 17% in atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: